Fisher Asset Management
ALNY icon

Fisher Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fisher Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Buy
6,252
+207
+3% +$62.4K ﹤0.01% 605
2026
Q1 		$2M Buy
+6,045
New +$2.06M ﹤0.01% 575

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management's ALNY Position: Q2 2026 in Review

Fisher Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 3.4% in Q2 2026, buying an estimated $62.4K and bringing the position to 6,252 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #605.

Fisher Asset Management first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $2M in Q1 2026. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Fisher Asset Management held 6,252 shares of Alnylam Pharmaceuticals worth $1.88M as of Q2 2026.
  • Fisher Asset Management bought 207 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $62.4K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Fisher Asset Management's portfolio in Q2 2026, its #605 holding.
  • Fisher Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Fisher Asset Management's Alnylam Pharmaceuticals position peaked at $2M in Q1 2026.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.